Acrivon Therapeutics, Inc (ACRV) insider trading
Every open-market stock purchase and sale by Acrivon Therapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Insiders bought $114K over the last 12 months (3 buys).
- Last insider buy: Peter Blume-Jensen (CEO), $82.1K, 9 months ago.
Last 12 months: insiders bought $114K (3 buys) and sold $0 (0 sales). Last close $1.38 on Jun 10, 2026.
Recent ACRV insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Jun 17, 2026 | Ra Capital Management L.p. (Insider) | Bought (not open market) | — |
| Jun 17, 2026 | Charles M Baum (Insider) | Bought (not open market) | — |
| Jun 17, 2026 | Derek DiRocco (Insider) | Bought (not open market) | — |
| Jun 17, 2026 | Ivana Magovcevic-Liebisch (Insider) | Bought (not open market) | — |
| Jun 17, 2026 | Santhosh Palani (Insider) | Bought (not open market) | — |
| Jun 17, 2026 | Sharon Shacham (Insider) | Bought (not open market) | — |
| Jun 17, 2026 | Michael John Tomsicek (Insider) | Bought (not open market) | — |
| May 21, 2026 | Peter Blume-Jensen (CEO) | Sold (not open market) | $24.6K |
| May 18, 2026 | Derek DiRocco (Insider) | Bought (not open market) | — |
| May 18, 2026 | Ra Capital Management L.p. (Insider) | Bought (not open market) | — |
| May 18, 2026 | Michael John Tomsicek (Insider) | Bought (not open market) | — |
| May 18, 2026 | Sharon Shacham (Insider) | Bought (not open market) | — |
| May 18, 2026 | Santhosh Palani (Insider) | Bought (not open market) | — |
| May 18, 2026 | Ivana Magovcevic-Liebisch (Insider) | Bought (not open market) | — |
| May 18, 2026 | Charles M Baum (Insider) | Bought (not open market) | — |
| May 18, 2026 | Katharine Peterson (C-suite exec) | Bought (not open market) | — |
| May 18, 2026 | Mansoor Raza Mirza (C-suite exec) | Bought (not open market) | — |
| May 18, 2026 | Mary Miller (C-suite exec) | Bought (not open market) | — |
| May 18, 2026 | Adam D. Levy (CFO) | Bought (not open market) | — |
| May 18, 2026 | Erick Gamelin (C-suite exec) | Bought (not open market) | — |
| May 18, 2026 | Eric Devroe (COO) | Bought (not open market) | — |
| May 18, 2026 | Peter Blume-Jensen (CEO) | Bought (not open market) | — |
| May 18, 2026 | Peter Blume-Jensen (CEO) | Bought (not open market) | — |
| May 14, 2026 | Peter Blume-Jensen (CEO) | Sold (not open market) | $2.4K |
| May 14, 2026 | Eric Devroe (COO) | Sold (not open market) | $1.2K |
Who's trading ACRV
- Charles M Baum, Insider: other filings, last Jun 17, 2026
- Derek DiRocco, Insider: other filings, last Jun 17, 2026
- Ivana Magovcevic-Liebisch, Insider: other filings, last Jun 17, 2026
- Santhosh Palani, Insider: other filings, last Jun 17, 2026
- Ra Capital Management L.p., Insider: other filings, last Jun 17, 2026
- Sharon Shacham, Insider: other filings, last Jun 17, 2026
- Michael John Tomsicek, Insider: other filings, last Jun 17, 2026
- Peter Blume-Jensen, CEO: bought $82.1K (1 buy), last May 21, 2026
- Katharine Peterson, C-suite exec: other filings, last May 18, 2026
- Mary Miller, C-suite exec: other filings, last May 18, 2026
- Mansoor Raza Mirza, C-suite exec: other filings, last May 18, 2026
- Adam D. Levy, CFO: bought $15K (1 buy), last May 18, 2026
- Eric Devroe, COO: bought $17.2K (1 buy), last May 18, 2026
- Erick Gamelin, C-suite exec: other filings, last May 18, 2026
Get free alerts when an insider at Acrivon Therapeutics, Inc files a new trade →